Clinical Trials

Mirati Sponsored

Mirati is currently sponsoring clinical trials in multiple programs. Click on a clinical trial below to learn more.

Sitravatinib (MGCD516)

Study 516-005 - Phase 3 of sitravatinib in combination for NSCLC

Phase 3 pivotal trial of sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy in combination with checkpoint inhibitor therapy (Study 516-005)

See details for this study at clinicaltrials.gov

Study 516-003 - Phase 2 of sitravatinib in combination for urothelial carcinoma

Phase 2 clinical trial of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma (Study 516-003)

See details for this study at clinicaltrials.gov

Study 516-002 - Phase 2 of sitravatinib in combination for clear cell renal cell cancer

Phase 2 neo-Adjuvant clinical trial of sitravatinib in combination with nivolumab in patients with clear cell renal cell cancer (Study 516-002)

See details for this study at clinicaltrials.gov

Study 516-001 - Phase 1b of sitravatinib single agent for solid tumors with the CBL gene mutation

KRAS G12C Inhibitor (MRTX849)

Study 849-001 - Phase 1b/2 of single agent MRTX849 for solid tumors with KRAS G12C mutation

Phase 1b/2 clinical trial of single agent MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.

See details for this study at clinicaltrials.gov

To identify clinical trials that match your diagnosis, treatment history and location, call 1-844-893-5530 or use our online Study Locator

This information is not intended to replace the informed medical advice or medical treatments of a health care professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient or whether enrollment in a clinical trial is appropriate for a patient. If you have questions regarding appropriate treatment of your medical condition, you must consult a suitably qualified healthcare professional.